Dr Lalchandani Labs has successfully completed its rights issue allotment, marking a significant milestone in the company's capital expansion strategy. The pathology laboratory company announced the allotment of 43,04,000 fully paid-up equity shares on March 02, 2026, effectively doubling its paid-up share capital through a formal disclosure to BSE Limited under SEBI Listing Regulations.

Rights Issue Structure and Timeline

The rights issue was initially disclosed on January 20, 2026, with the company proposing to raise ₹430.40 lakhs through the issuance of equity shares. The subscription period commenced on February 04, 2026, and concluded on February 27, 2026, providing eligible shareholders with the opportunity to subscribe to new shares at par value.

Share Capital Transformation

The allotment has resulted in a substantial increase in the company's equity base, with the paid-up share capital witnessing a complete doubling following the successful rights issue completion. The shares were allotted to eligible shareholders and renouncees as per the finalized basis of allotment.

Board Approval and Regulatory Process

The Board of Directors convened on March 02, 2026, from 07:00 PM to 07:55 PM to formalize the allotment decision. The approval process involved consultation with Cameo Corporate Services Limited, serving as the registrar to the issue, and received necessary approvals from BSE Limited as the designated stock exchange for the rights issue.

The allotment was conducted in accordance with the Letter of Offer dated January 20, 2026, ensuring compliance with SEBI Listing Regulations under Regulation 30. The formal disclosure was communicated to BSE Limited at Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai, maintaining transparency with the stock exchange.

Corporate Governance and Disclosure

The disclosure demonstrates the company's commitment to transparency and regulatory compliance, with all relevant information made available on the company's website at lalchandanipathlab.com. The formal communication was digitally signed by Arjan Lalchandani, Managing Director (DIN: 07014579), ensuring proper corporate authorization for this significant capital market transaction.

Dr lalchandani labs Limited has announced an extension of its ongoing rights issue closing date following a board meeting held on February 16, 2026. The company has now published newspaper advertisements on February 17, 2026, formally notifying stakeholders about the extension.

Rights Issue Extension Details

The company's board of directors approved the extension of the rights issue closing date during their meeting on February 16, 2026. The rights issue, which commenced on February 04, 2026, was initially scheduled to conclude on February 20, 2026, but has now been extended by one week to February 27, 2026.

Alongside the main issue extension, the company has also extended the deadline for on-market trading in rights entitlements. The trading window, originally set to close on February 17, 2026, has been extended to Tuesday, February 24, 2026.

Newspaper Publication and Regulatory Compliance

On February 17, 2026, Dr Lalchandani Labs Limited published newspaper advertisements in Financial Express (English - All Edition) and Jansatta (Hindi - All editions) to formally communicate the extension details to all stakeholders. The publication was submitted to BSE Limited with scrip code 541299, signed by Managing Director Arjan Lal Chandani (DIN: 07014579).

Revised Rights Issue Timeline

The company has provided a comprehensive revised schedule for the rights issue process:

Board Meeting and Documentation

The board meeting commenced at 01.30 p.m. and concluded at 02:00 p.m. on February 16, 2026. The company has clarified that except for the extension of the issue closing date and consequential changes in the post-issue timeline, there are no other modifications to the Letter of Offer (LOF), Composite Application Form (CAF), or other issue-related documents, all dated January 20, 2026.

Rationale for Extension

The extension has been granted specifically to facilitate better participation from eligible shareholders and to provide them with adequate time to subscribe to the rights issue. This strategic decision demonstrates the company's commitment to ensuring maximum shareholder participation in the capital raising exercise.

The announcement was made in compliance with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, and the information is also available on the company's website at lalchandanipathlab.com.